Quantcast Archives 0507.html
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

May 2007

Telemedicine Addresses Rising Healthcare Costs
Dendreon Catches A Break From The Fda
Biotechs & Pharmas Bracing For Asco Annual Meeting
Biohealth Investor Looking For Contributors & Writers
Fda Green Lights Harvest’s Stem Cell Trial
Next-generation Psychology Treatments
Dendreon Volume And Volatility Compress Ahead Of Asco
Endocare Raises $7 Million
Celgene Could Do Well At Asco
Cancer Stocks On The Go: It’s Asco
New Device Outpaces Competition In Epilepsy Market
Vion Jumps On Heavy Volume, Then Plunges 60 Percent!
Compare And Contrast: Emea And Fda On Avandia
Networks Dramatize Diabetes Drug Dangers
Biowatch Alert: Vion Jumps On Strong Volume, No News
Congressional Hearing On Fda's Handling Of Avandia
Dendreon Interest Remains Extremely High
Thermogenesis Would Make A Great Acquisition Target
Champions Biotechnology To Buy Biomerk
Antigenics' Oncophage Data Boosts Shares
Federal Circuit Denies Pfizer's Petition For Rehearing In Norvasc Case
Dendreon's New Double-twist
Biowatch Alert: Arqule Could See 15% Gain Ahead Of Asco
Medical Buyouts Dominate Last Week's News
Is Early Release Of Study Data To Doctors Unfair?
Neurotech Investments On The Rise
Does Dusa Run Too Hard?
Oxycontin, Oxymorons And Oxyapologists
Eisai Defeats Dr. Reddy's And Teva In Aciphex Patent Suit
Bausch & Lomb Selling Itself Away Too Cheap
Robotic Devices Move Into The Mainstream…and Beyond
Amputee Rights
The Summer Of Sicko: Michael Moore's Film Makes Cannes Debut Today
Teknimed Inks Deal With Smith & Nephew
Mylan's Shareholders Act As Lbo Lenders
Abc And Cbs Give No Credit To Novartis
Bluesky May Make $110 Million Off Smith & Nephew Deal
Blogfile: Targacept, Inc. (trgt)
Blogfile: Dendreon Corporation (dndn)
Critical Therapeutics: Another Company In “less Crowded Water”
Rantasorous Rx
Comments From Dendreon's Conference Call (may 10, 2007)
Protesters At Bio2007 Fear Unintended Consequences
Does Fda Need A Statutory Path To Approve Follow-on Biologics?
Schwarz Out In Front With Parkinson’s Patch
Fda Reform Advances - But Is It Enough?
When A $0 Copay Is Too High
Dendreon Gets Complete Response Letter
Generic Surgical Mesh Hits Market
More On Melamine
Dendreon Nailed By Fda
Joint Venture Into Drug-eluting Stents
Dendreon Option Premiums Remain Astronomical
Credibility And Prosperity In Biotech
Michael J. Fox Outlines Need For New Treatments At Bio.2007
Dendreon, A Biotech Gift That Keeps On Giving!
New Company Launches To Help Truckers Stay Awake
The Critical Path Of The Critical Path
Dendreon's New 'hold' Rating At A.g.edwards
Bruker's Stock Plunge An Over-reaction
Bruker's Profits Increase, So Why The 20% Drop?
Low Visibility Led To Enpath Acquisition
Melamine Creep
District Court Denies All Challenges To Fda Decision On Norvasc Exclusivity

<< Home

Stock Quote or
Examples
Underground Trading - Sat May 10, 2008 04:02PM
This is an update on my speculative long term position p [read more]
Morpheus Trading - Mon May 12, 2008 04:25AM
NOTE: Please click on the charts below to enlarge them if [read more]
Millionaire Now! by Larry Nusbaum - Mon May 12, 2008 04:54AM
MORNING MARKET COMMENTARYfor Monday, May 12, 2008Weak Financ [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.